Tag: psychiatric disorders
University of Sydney spinout bags $273m for psychiatric drug dev’t
Kinoxis Therapeutics, a University of Sydney spinoff, announced a partnership with German pharmaceutical company Boehringer Ingelheim to develop precision therapies that target oxytocin aimed at enhancing the quality of life for people with psychiatric disorders.
Featured Article
From cost exposure to cost control: Using energy flexibility to protect margins
Electricity price volatility is reshaping the cost base of Australian manufacturing, challenging long-held assumptions that energy can be treated as a stable operational input.
